Novo Nordisk Partners with OpenAI for Full-Business AI Integration — Drug Discovery Through Supply Chain

Crescendo AI·medium signal

Danish pharmaceutical giant Novo Nordisk announced a strategic partnership with OpenAI to integrate AI across its entire business — from drug discovery and clinical trials to manufacturing, supply chains, and commercial operations — with full deployment planned by end of 2026. This is one of the most comprehensive enterprise AI adoption deals to date, going well beyond the typical 'customer support chatbot' use case.